A phase 1B inpatient, randomized, double-blind, placebo-controlled, crossover study of the safety and efficacy of two fixed doses of PF-3463275 in adjunctive treatment of cognitive deficits in schizophrenia.
Phase of Trial: Phase I
Latest Information Update: 19 May 2008
At a glance
- Drugs PF 3463275 (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Pfizer
- 11 Dec 2007 New trial record.